相关实验视频
Updated: Sep 17, 2025

06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
331
性结肠炎的肠急性:基线急性的影响和急性的变化对mirikizumab的反应
David B Clemow1, Marla C Dubinsky2, Simin K Baygani3
1Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. clemow_david_b@lilly.com.
Journal of patient-reported outcomes
|July 1, 2025
概括
米里基祖马布改善了性结肠炎的症状,包括肠道急迫症,无论基线严重程度如何. 即使没有达到其他结局的患者也看到与安慰剂相比,mirikizumab的急性改善.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 患者报告的结果
背景情况:
- 米里基祖马布在中度至重度的性结肠炎中显示出有效性.
- 紧急数值评分表 (NRS) 的1-2点变化表明有意义的改善.
- 这项研究分析了基于基线肠急症严重程度的mirikizumab的疗效.
研究的目的:
- 评估mirikizumab在性结肠炎患者中的疗效.
- 在不同基线紧急NRS得分组中比较mirikizumab与安慰剂.
- 评估mirikizumab对随时间推移肠急症严重性的影响.
主要方法:
- 紧急NRS在基线,第12周和第52周测量.
- 在患者达到或未达到疗效终点时评估的肠急性改善.
- 用于数据分析的非响应者归算的费舍尔精确测试.
主要成果:
- 米里基祖马布显著增加了临床反应和缓解率与安慰剂相比,无论基线紧急NRS.
- 较高比例的mirikizumab患者实现了临床,内镜和症状缓解 (三角形9%-45%).
- 在mirikizumab患者中观察到紧急NRS改善,无论其他疗效结局是否得到满足 (13%-90%对12%-75%).
结论:
- 与安慰剂相比,mirikizumab治疗导致性结肠炎患者的缓解率更高,独立于最初的肠急症.
- 一年后,Mirikizumab在肠道急迫性方面表现出卓越的改善,即使在没有达到其他临床结果的患者中也是如此.
- 肠急症的改善与改善的生活质量相关;紧急NRS监测有助于评估结果.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
Drugs for Treatment of Diarrhea-Predominant IBS
312
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312
Drugs for Treatment of Constipation-Predominant IBS
351
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
351
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Inflammatory Bowel Disease I: Ulcerative Colitis
342
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
342
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208

